Drug Details
General Information of the Drug (ID: DR9477) | ||||
---|---|---|---|---|
Name |
IPI-549
|
|||
Synonyms |
XUMALORDVCFWKV-IBGZPJMESA-N; IPI549; 1693758-51-8; CHEMBL3984425; GTPL9563; SCHEMBL16629991; IPI 549; MolPort-044-756-207; EX-A1057; s8330; BDBM50192880; ZINC584906867; AKOS030627132; CS-6106; compound 26 [PMID: 27660692]; AC-29898; HY-100716; Pyrazolo[1,5-a]pyrimidine-3-carboxamide, 2-amino-N-[(1S)-1-[1,2-dihydro-8-[2-(1-methyl-1H-pyrazol-4-yl)ethynyl]-1-oxo-2-phenyl-3-isoquinolinyl]ethyl]-; 2-amino-N-[(1S)-1-[8-[2-(1-methylpyrazol-4-yl)ethynyl]-1-oxo-2-phenylisoquinolin-3-yl]ethyl]pyrazolo[1,5-a]pyrimidine-3-carboxamide; (S)-2-amino-N-(1-(8-((
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Solid tumour/cancer [ICD-11: 2A00-2F9Z] | Phase 1 | [1] | |
Structure |
![]() |
Click to Download Mol2D MOL |
||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
C30H24N8O2
|
|||
PubChem CID | ||||
Canonical SMILES |
CC(C1=CC2=C(C(=CC=C2)C#CC3=CN(N=C3)C)C(=O)N1C4=CC=CC=C4)NC(=O)C5=C6N=CC=CN6N=C5N
|
|||
InChI |
1S/C30H24N8O2/c1-19(34-29(39)26-27(31)35-37-15-7-14-32-28(26)37)24-16-22-9-6-8-21(13-12-20-17-33-36(2)18-20)25(22)30(40)38(24)23-10-4-3-5-11-23/h3-11,14-19H,1-2H3,(H2,31,35)(H,34,39)/t19-/m0/s1
|
|||
InChIKey |
XUMALORDVCFWKV-IBGZPJMESA-N
|
|||
CAS Number |
CAS 1693758-51-8
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Silibinin | Carduus marianus | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) |
Combination Info
![]() |
|||||
Biological
Regulation |
Down-regulation | Regulatory T cells and myeloid suppressor cells | ||||
In-vivo Model | 4T1 cells was inoculated subcutaneously into the right mammary glands of female balb/c mice. | |||||
Experimental
Result(s) |
Tumor-targeted delivery of silibinin and IPI-549 synergistically inhibit breast cancer by remodeling the microenvironment. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | PI3-kinase gamma (PIK3CG) | Molecule Info | [1] | |
KEGG Pathway | Inositol phosphate metabolism | Click to Show/Hide | ||
2 | ErbB signaling pathway | |||
3 | Ras signaling pathway | |||
4 | Rap1 signaling pathway | |||
5 | cGMP-PKG signaling pathway | |||
6 | cAMP signaling pathway | |||
7 | Chemokine signaling pathway | |||
8 | HIF-1 signaling pathway | |||
9 | FoxO signaling pathway | |||
10 | Phosphatidylinositol signaling system | |||
11 | Sphingolipid signaling pathway | |||
12 | mTOR signaling pathway | |||
13 | PI3K-Akt signaling pathway | |||
14 | AMPK signaling pathway | |||
15 | Apoptosis | |||
16 | Adrenergic signaling in cardiomyocytes | |||
17 | VEGF signaling pathway | |||
18 | Osteoclast differentiation | |||
19 | Focal adhesion | |||
20 | Signaling pathways regulating pluripotency of stem cells | |||
21 | Platelet activation | |||
22 | Toll-like receptor signaling pathway | |||
23 | Jak-STAT signaling pathway | |||
24 | Natural killer cell mediated cytotoxicity | |||
25 | T cell receptor signaling pathway | |||
26 | B cell receptor signaling pathway | |||
27 | Fc epsilon RI signaling pathway | |||
28 | Fc gamma R-mediated phagocytosis | |||
29 | TNF signaling pathway | |||
30 | Leukocyte transendothelial migration | |||
31 | Neurotrophin signaling pathway | |||
32 | Cholinergic synapse | |||
33 | Inflammatory mediator regulation of TRP channels | |||
34 | Regulation of actin cytoskeleton | |||
35 | Insulin signaling pathway | |||
36 | Progesterone-mediated oocyte maturation | |||
37 | Estrogen signaling pathway | |||
38 | Prolactin signaling pathway | |||
39 | Thyroid hormone signaling pathway | |||
40 | Oxytocin signaling pathway | |||
41 | Regulation of lipolysis in adipocytes | |||
42 | Type II diabetes mellitus | |||
43 | Non-alcoholic fatty liver disease (NAFLD) | |||
44 | Aldosterone-regulated sodium reabsorption | |||
45 | Carbohydrate digestion and absorption | |||
46 | Bacterial invasion of epithelial cells | |||
47 | Chagas disease (American trypanosomiasis) | |||
48 | Toxoplasmosis | |||
49 | Amoebiasis | |||
50 | Hepatitis C | |||
51 | Hepatitis B | |||
52 | Measles | |||
53 | Influenza A | |||
54 | HTLV-I infection | |||
55 | Epstein-Barr virus infection | |||
56 | Pathways in cancer | |||
57 | Viral carcinogenesis | |||
58 | Proteoglycans in cancer | |||
59 | MicroRNAs in cancer | |||
60 | Colorectal cancer | |||
61 | Renal cell carcinoma | |||
62 | Pancreatic cancer | |||
63 | Endometrial cancer | |||
64 | Glioma | |||
65 | Prostate cancer | |||
66 | Melanoma | |||
67 | Chronic myeloid leukemia | |||
68 | Acute myeloid leukemia | |||
69 | Small cell lung cancer | |||
70 | Non-small cell lung cancer | |||
71 | Central carbon metabolism in cancer | |||
72 | Choline metabolism in cancer | |||
Pathwhiz Pathway | Inositol Metabolism | Click to Show/Hide | ||
2 | Phosphatidylinositol Phosphate Metabolism | |||
3 | Intracellular Signalling Through Adenosine Receptor A2a and Adenosine | |||
4 | Intracellular Signalling Through Adenosine Receptor A2b and Adenosine | |||
5 | Fc Epsilon Receptor I Signaling in Mast Cells | |||
Reactome | PI3K Cascade | Click to Show/Hide | ||
2 | GPVI-mediated activation cascade | |||
3 | Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants | |||
4 | PI3K events in ERBB4 signaling | |||
5 | PIP3 activates AKT signaling | |||
6 | GAB1 signalosome | |||
7 | PI3K events in ERBB2 signaling | |||
8 | PI3K/AKT activation | |||
9 | Role of phospholipids in phagocytosis | |||
10 | Tie2 Signaling | |||
11 | Constitutive Signaling by Aberrant PI3K in Cancer | |||
12 | DAP12 signaling | |||
13 | Role of LAT2/NTAL/LAB on calcium mobilization | |||
14 | Nephrin interactions | |||
15 | Costimulation by the CD28 family | |||
16 | CD28 dependent PI3K/Akt signaling | |||
17 | G beta:gamma signalling through PI3Kgamma | |||
18 | G alpha (q) signalling events | |||
19 | G alpha (12/13) signalling events | |||
20 | VEGFA-VEGFR2 Pathway | |||
21 | Interleukin-3, 5 and GM-CSF signaling | |||
22 | Constitutive Signaling by EGFRvIII | |||
23 | PI-3K cascade:FGFR1 | |||
24 | PI-3K cascade:FGFR2 | |||
25 | PI-3K cascade:FGFR3 | |||
26 | PI-3K cascade:FGFR4 | |||
27 | Interleukin receptor SHC signaling | |||
28 | Regulation of signaling by CBL | |||
WikiPathways | Toll-like receptor signaling pathway | Click to Show/Hide | ||
2 | Serotonin HTR1 Group and FOS Pathway | |||
3 | DNA Damage Response (only ATM dependent) | |||
4 | G13 Signaling Pathway | |||
5 | Regulation of Actin Cytoskeleton | |||
6 | Insulin Signaling | |||
7 | IL-4 Signaling Pathway | |||
8 | Copper homeostasis | |||
9 | Signaling of Hepatocyte Growth Factor Receptor | |||
10 | Transcriptional activation by NRF2 | |||
11 | IL1 and megakaryotyces in obesity | |||
12 | Signaling by ERBB4 | |||
13 | Signaling by ERBB2 | |||
14 | Fc epsilon receptor (FCERI) signaling | |||
15 | PI Metabolism | |||
16 | Interleukin-2 signaling | |||
17 | Fcgamma receptor (FCGR) dependent phagocytosis | |||
18 | Signaling by SCF-KIT | |||
19 | DAP12 interactions | |||
20 | Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R) | |||
21 | Gastrin-CREB signalling pathway via PKC and MAPK | |||
22 | PIP3 activates AKT signaling | |||
23 | Integrated Pancreatic Cancer Pathway | |||
24 | Prostate Cancer | |||
25 | Signaling Pathways in Glioblastoma | |||
26 | TSLP Signaling Pathway | |||
27 | Regulation of Microtubule Cytoskeleton | |||
28 | TSH signaling pathway | |||
29 | SREBP signalling | |||
30 | TCR signaling | |||
31 | Signaling by PDGF | |||
32 | Signaling by Insulin receptor | |||
33 | Signaling by FGFR | |||
34 | Signaling by EGFR | |||
35 | NGF signalling via TRKA from the plasma membrane | |||
36 | Nephrin interactions | |||
37 | Interleukin-3, 5 and GM-CSF signaling | |||
38 | GPVI-mediated activation cascade | |||
39 | GPCR downstream signaling | |||
40 | Costimulation by the CD28 family | |||
41 | Cell surface interactions at the vascular wall | |||
42 | MicroRNAs in cardiomyocyte hypertrophy | |||
43 | Angiogenesis | |||
44 | Regulation of toll-like receptor signaling pathway | |||
45 | AMPK Signaling |
